Amedeo Smart

Free Medical Literature Service

 

Amedeo

Liver Diseases
  Free Subscription

Articles published in
J Gastroenterol Hepatol
    April 2024
  1. OHAMA H, Hiraoka A, Tada T, Kariyama K, et al
    Changes in clinical outcomes in Japanese patients with hepatocellular carcinoma due to hepatitis C virus following the development of direct-acting antiviral agents.
    J Gastroenterol Hepatol. 2024 Apr 11. doi: 10.1111/jgh.16553.
    >> Share

  2. CHAN WK, George J
    Metabolic fatty liver syndromes: where do we stand in 2024?
    J Gastroenterol Hepatol. 2024;39:613-614.
    >> Share

  3. PARENTE A, Milana F, Hajibandeh S, Hajibandeh S, et al
    Clinical outcomes after transplantation of domino grafts or standard deceased donor livers: a systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2024;39:620-629.
    >> Share

    March 2024
  4. WANG X, Liu H, Wang Y, Wang P, et al
    Novel protein C6ORF120 promotes liver fibrosis by activating hepatic stellate cells through the PI3K/Akt/mTOR pathway.
    J Gastroenterol Hepatol. 2024 Mar 24. doi: 10.1111/jgh.16538.
    >> Share

  5. SUZUKI K, Yasui Y, Tsuchiya K, Matsumoto H, et al
    Impact of immune-related adverse events in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
    J Gastroenterol Hepatol. 2024 Mar 17. doi: 10.1111/jgh.16532.
    >> Share

  6. BALE G, Kulkarni AV, Padaki NR, Menon PB, et al
    Comparing rare variants versus common in the pathogenesis of nonalcoholic fatty liver disease: a whole exome sequencing approach.
    J Gastroenterol Hepatol. 2024;39:587-595.
    >> Share

    February 2024

  7. Correction to "Hepatobiliary and Pancreatic: Challenges in the diagnosis of hepatic nodules in patients with alcoholic liver cirrhosis".
    J Gastroenterol Hepatol. 2024 Feb 25. doi: 10.1111/jgh.16529.
    >> Share

  8. TADA T, Kumada T, Hiraoka A, Kariyama K, et al
    mADRES predicts hepatocellular carcinoma development in patients with hepatitis C virus who achieved sustained virological response.
    J Gastroenterol Hepatol. 2024 Feb 25. doi: 10.1111/jgh.16512.
    >> Share

  9. WANG J, Zhang Y, Ma Y, Zhao S, et al
    TET1 inhibits liver fibrosis by blocking hepatic stellate cell activation.
    J Gastroenterol Hepatol. 2024 Feb 18. doi: 10.1111/jgh.16443.
    >> Share

  10. BATT NM, Rodrigues B, Bloom S, Sawhney R, et al
    Metabolic-associated fatty liver disease and hepatocellular carcinoma: a prospective study of characteristics and response to therapy.
    J Gastroenterol Hepatol. 2024 Feb 18. doi: 10.1111/jgh.16501.
    >> Share

  11. HAHN JW, Lee H, Shin M, Seong MW, et al
    Diagnostic algorithm for neonatal intrahepatic cholestasis integrating single-gene testing and next-generation sequencing in East Asia.
    J Gastroenterol Hepatol. 2024 Feb 7. doi: 10.1111/jgh.16505.
    >> Share

  12. JI PX, Chen YX, Ni XX, Miao Q, et al
    Effect of triggering receptor expressed on myeloid cells 2-associated alterations on lipid metabolism in macrophages in the development of non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2024;39:369-380.
    >> Share

    January 2024
  13. TOYODA H, Tada T, Uojima H, Nozaki A, et al
    Comparison of six hepatocellular carcinoma prediction models in Japanese patients after sustained virologic response undergoing rigorous surveillance for hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2024 Jan 30. doi: 10.1111/jgh.16494.
    >> Share

  14. AMJAD W, Jiang Z, Lai M
    Statin use in cirrhosis and its association with incidence of portal vein thrombosis.
    J Gastroenterol Hepatol. 2024 Jan 25. doi: 10.1111/jgh.16495.
    >> Share

  15. DIAO L, Wang C, You R, Leng B, et al
    Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE.
    J Gastroenterol Hepatol. 2024 Jan 19. doi: 10.1111/jgh.16463.
    >> Share

  16. ZHU J, Xia Y, Liu X, Zhang C, et al
    Preventing variceal rebleeding in cirrhotic patients with portal vein thrombosis: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2024 Jan 17. doi: 10.1111/jgh.16489.
    >> Share

  17. NIE MT, Wang PQ, Shi PM, Hong XL, et al
    Rifaximin treatment shapes a unique metagenome-metabolism network in patients with decompensated cirrhosis.
    J Gastroenterol Hepatol. 2024 Jan 17. doi: 10.1111/jgh.16484.
    >> Share

  18. SOGABE M, Okahisa T, Kagawa M, Sei M, et al
    Association of metabolic dysfunction-associated fatty liver disease with gallstone development: A longitudinal study.
    J Gastroenterol Hepatol. 2024 Jan 11. doi: 10.1111/jgh.16483.
    >> Share

    December 2023
  19. GOPAL P, Banerjee D, Karad A, Dandi K, et al
    Gastrointestinal: Congenital portosystemic shunt (Abernathy type 2) with cirrhosis of liver.
    J Gastroenterol Hepatol. 2023 Dec 26. doi: 10.1111/jgh.16456.
    >> Share

  20. CHO SH, Song TJ, Oh D, Park DH, et al
    Endoscopic ultrasound-guided hepaticoduodenostomy versus percutaneous drainage for right intrahepatic duct dilatation in malignant hilar obstruction.
    J Gastroenterol Hepatol. 2023 Dec 18. doi: 10.1111/jgh.16442.
    >> Share

  21. TOSHIDA K, Itoh S, Yoshiya S, Nagao Y, et al
    Pretreatment eosinophil count predicts response to atezolizumab plus bevacizumab therapy in patients with hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2023 Dec 12. doi: 10.1111/jgh.16441.
    >> Share

  22. HUANG X, Zhou LZ, Feng WJ, Liu YQ, et al
    Circ ubiquitin-like-containing plant homeodomain and RING finger domains protein 1 increases the stability of G9a and ubiquitin-like-containing plant homeodomain and RING finger domains protein 1 messenger RNA through recruiting eukaryotic translation
    J Gastroenterol Hepatol. 2023 Dec 7. doi: 10.1111/jgh.16408.
    >> Share

  23. YANG Y, Liu S, Li H, Liu Y, et al
    The protective effect of Nostoc commune Vauch. polysaccharide on alcohol-induced acute alcoholic liver disease and gut microbiota disturbance in mice.
    J Gastroenterol Hepatol. 2023;38:2185-2194.
    >> Share

  24. TONG C, Halengbieke A, Ni X, Han Y, et al
    Bidirectional relationship between nonalcoholic fatty liver disease and serum creatinine-to-body weight ratio as a proxy for skeletal muscle mass index.
    J Gastroenterol Hepatol. 2023;38:2061-2069.
    >> Share

  25. NARANG M, Shah D, Narang S, Gupta N, et al
    Ultrasound-guided aspiration in addition to antibiotics for treatment of liver abscess in children: A randomized controlled trial.
    J Gastroenterol Hepatol. 2023;38:2070-2075.
    >> Share

    November 2023
  26. SHI L, Feng G, Yang X, Zhang Y, et al
    Potential of PAQosome as a therapeutic target for hepatic fibrosis.
    J Gastroenterol Hepatol. 2023 Nov 28. doi: 10.1111/jgh.16427.
    >> Share

  27. DU S, Cao K, Yan Y, Wang Y, et al
    Developments and current status of cell-free DNA in the early detection and management of hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2023 Nov 21. doi: 10.1111/jgh.16416.
    >> Share

  28. ALLAIRE M, Thabut D
    The applicability of Baveno criteria in the setting of hepatocellular carcinoma remains a controversy.
    J Gastroenterol Hepatol. 2023 Nov 21. doi: 10.1111/jgh.16415.
    >> Share

  29. FAROOQ U, Tarar ZI, El Alayli A, Kamal F, et al
    Analyzing the utility of renal replacement therapy to manage hepatorenal syndrome in alcoholic hepatitis without liver transplantation: a nationwide analysis.
    J Gastroenterol Hepatol. 2023 Nov 12. doi: 10.1111/jgh.16388.
    >> Share

  30. SUN J
    Navigating the complex landscape of non-alcoholic fatty liver disease: From genomic associate to the AMPK/mTOR pathways.
    J Gastroenterol Hepatol. 2023;38:1863-1864.
    >> Share

  31. TIAN Y, Wang B
    Unraveling the pathogenesis of non-alcoholic fatty liver diseases through genome-wide association studies.
    J Gastroenterol Hepatol. 2023;38:1877-1885.
    >> Share

  32. WANG Y, Huang Y, Zheng T, Sun C, et al
    Gastrointestinal hospitalization during COVID-19 pandemic in the United States: Analysis of a nationwide inpatient sample.
    J Gastroenterol Hepatol. 2023;38:1971-1979.
    >> Share

  33. TAKAHASHI A, Takahata Y, Kokubun M, Anzai Y, et al
    Association between equol and non-alcoholic fatty liver disease in Japanese women in their 50s and 60s.
    J Gastroenterol Hepatol. 2023;38:1958-1962.
    >> Share

  34. MARCONDES-DE-CASTRO IA, Reis-Barbosa PH, Marinho TS, Aguila MB, et al
    AMPK/mTOR pathway significance in healthy liver and non-alcoholic fatty liver disease and its progression.
    J Gastroenterol Hepatol. 2023;38:1868-1876.
    >> Share

    October 2023
  35. QUAN Y, Shou D, Yang S, Cheng J, et al
    Mdivi1 ameliorates mitochondrial dysfunction in non-alcoholic steatohepatitis by inhibiting JNK/MFF signaling.
    J Gastroenterol Hepatol. 2023 Oct 15. doi: 10.1111/jgh.16372.
    >> Share

  36. OH JH, Saeed WK, Kim HY, Lee SM, et al
    Hepatic stellate cells activate and avoid death under necroptosis stimuli: Hepatic fibrosis during necroptosis.
    J Gastroenterol Hepatol. 2023 Oct 9. doi: 10.1111/jgh.16368.
    >> Share

  37. GIRI S, Singh A, Kolhe K, Kale A, et al
    Reply: Portal vein thrombosis in cirrhosis: exploring the uncharted waters.
    J Gastroenterol Hepatol. 2023 Oct 7. doi: 10.1111/jgh.16378.
    >> Share

  38. SHOU D, Luo Q, Tang W, Cao C, et al
    Hepatobiliary and pancreatic: Multi-donor fecal microbiota transplantation attenuated high-fat diet-induced hepatic steatosis in mice by remodeling the gut microbiota.
    J Gastroenterol Hepatol. 2023 Oct 3. doi: 10.1111/jgh.16359.
    >> Share

  39. ITO T, Morooka H, Takahashi H, Fujii H, et al
    Identification of clinical phenotypes associated with poor prognosis in patients with nonalcoholic fatty liver disease via unsupervised machine learning.
    J Gastroenterol Hepatol. 2023;38:1832-1839.
    >> Share

  40. VAZ K, Kemp W, Majeed A, Lubel J, et al
    Non-alcoholic fatty liver disease prevalence in Australia has risen over 15 years in conjunction with increased prevalence of obesity and reduction in healthy lifestyle.
    J Gastroenterol Hepatol. 2023;38:1823-1831.
    >> Share

  41. RONG L, Ch'ng D, Jia P, Tsoi KKF, et al
    Use of probiotics, prebiotics, and synbiotics in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2023;38:1682-1694.
    >> Share

  42. TAKAHASHI Y, Seko Y, Yamaguchi K, Takeuchi K, et al
    Gamma-glutamyl transferase predicts pemafibrate treatment response in non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2023;38:1743-1749.
    >> Share

    September 2023
  43. KANG SH, Kim MY, Han SK, Baik SK, et al
    Subclinical diabetes confirmed by 75-g OGTT influence on the prognosis of decompensated cirrhosis.
    J Gastroenterol Hepatol. 2023 Sep 11. doi: 10.1111/jgh.16327.
    >> Share

  44. HIRATA K, Yamamoto Y, Hatanaka K, Kinoshita K, et al
    Hepatobiliary and pancreatic: Tiny pigmented intra-hepatic ducts stones as the cause of jaundice and liver failure.
    J Gastroenterol Hepatol. 2023 Sep 8. doi: 10.1111/jgh.16350.
    >> Share

  45. GASPAR R, Silva M, Cardoso P, Goncalves R, et al
    Spleen stiffness: a new tool to predict high-risk varices in cirrhotic patients.
    J Gastroenterol Hepatol. 2023 Sep 1. doi: 10.1111/jgh.16344.
    >> Share

  46. MURAKAMI S, Uchida T, Imamura M, Suehiro Y, et al
    Correlation between serum pro-inflammatory cytokine levels and the prognosis of the patients with acute liver failure.
    J Gastroenterol Hepatol. 2023;38:1637-1646.
    >> Share

  47. HAN E, Chun HS, Lee YH, Lee JS, et al
    MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study.
    J Gastroenterol Hepatol. 2023;38:1598-1609.
    >> Share

    August 2023
  48. HAYASHI H, Sawada K, Tanaka H, Muro K, et al
    The effect of heat-killed Lactobacillus brevis SBL88 on improving selective hepatic insulin resistance in non-alcoholic fatty liver disease mice without altering the gut microbiota.
    J Gastroenterol Hepatol. 2023 Aug 30. doi: 10.1111/jgh.16337.
    >> Share

  49. JIANG H, Xu N, Zhang W, Wei H, et al
    Do gut microbiome-targeted therapies improve liver function in cirrhotic patients? A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2023 Aug 15. doi: 10.1111/jgh.16329.
    >> Share

  50. ANIRVAN P
    Portal vein thrombosis in cirrhosis: exploring the uncharted waters.
    J Gastroenterol Hepatol. 2023 Aug 12. doi: 10.1111/jgh.16328.
    >> Share

  51. KIM K, Lee HW, Ahn SH
    How can we improve surveillance system for alcohol-associated hepatocellular carcinoma?
    J Gastroenterol Hepatol. 2023;38:1203-1204.
    >> Share

  52. CHEN M, Zhong W, Xu W
    Alcohol and the mechanisms of liver disease.
    J Gastroenterol Hepatol. 2023;38:1233-1240.
    >> Share

  53. ZHANG LY, Wang CY, Xu Q, Mu ZQ, et al
    Removal of epigenetic repressive mark on inflammatory genes in fat liver.
    J Gastroenterol Hepatol. 2023;38:1426-1437.
    >> Share

  54. JACOB R, Prince DS, Kench C, Liu K, et al
    Alcohol and its associated liver carcinogenesis.
    J Gastroenterol Hepatol. 2023;38:1211-1217.
    >> Share

  55. VIJAYALEKSHMI B, Choudhary A, Alexander V, Prabhu SB, et al
    Reticuloendothelial activation and phenotypic alteration of peripheral monocytes with enhanced liver recruitment drive liver injury secondary to yellow phosphorus.
    J Gastroenterol Hepatol. 2023;38:1408-1415.
    >> Share

  56. LI R, Liu J, Han P, Shi R, et al
    Associations between abdominal obesity indices and pathological features of non-alcoholic fatty liver disease: Chinese visceral adiposity index.
    J Gastroenterol Hepatol. 2023;38:1316-1324.
    >> Share

  57. CHETWOOD JD, Sabih AH, Chan K, Salimi S, et al
    Epidemiology, characteristics, and outcomes of patients with acute-on-chronic liver failure in Australia.
    J Gastroenterol Hepatol. 2023;38:1325-1332.
    >> Share

  58. JEW MH, Hsu CL
    Alcohol, the gut microbiome, and liver disease.
    J Gastroenterol Hepatol. 2023;38:1205-1210.
    >> Share

    July 2023
  59. CHO MS, Lee SK, Kwon JH, Nam SW, et al
    Hepatobiliary and Pancreatic: Challenges in the diagnosis of hepatic nodules in patients with alcoholic liver cirrhosis.
    J Gastroenterol Hepatol. 2023 Jul 10. doi: 10.1111/jgh.16277.
    >> Share

  60. CHOI WM, Yoo SY, Chang JI, Han S, et al
    A model for predicting poor survival in patients with cirrhosis undergoing portosystemic shunt embolization.
    J Gastroenterol Hepatol. 2023 Jul 7. doi: 10.1111/jgh.16280.
    >> Share

  61. LIU X, Wang J, Li M, Qiu J, et al
    Farnesoid X receptor is an important target for the treatment of disorders of bile acid and fatty acid metabolism in mice with nonalcoholic fatty liver disease combined with cholestasis.
    J Gastroenterol Hepatol. 2023 Jul 6. doi: 10.1111/jgh.16279.
    >> Share

  62. PODDAR U, Samanta A, Sarma MS, Kumar B, et al
    How to suspect the presence of high-risk esophageal varices and when to start endoscopic surveillance in children with biliary atresia?
    J Gastroenterol Hepatol. 2023 Jul 5. doi: 10.1111/jgh.16267.
    >> Share

  63. CHENG HY, Hu RH, Hsiao CY, Ho MC, et al
    Hepatitis C treatment and long-term outcome of patients with hepatocellular carcinoma after resection.
    J Gastroenterol Hepatol. 2023 Jul 4. doi: 10.1111/jgh.16276.
    >> Share

  64. LIU M, Qiu H, Zhang W, Mei T, et al
    Evaluation of blood-based PRO-C3 testing as a diagnostic marker for staging liver fibrosis: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2023;38:1018-1027.
    >> Share

  65. LIU P, Yao L, Hu X, Wang Z, et al
    Recent advances in the immunomodulation mechanism of mesenchymal stem cell therapy in liver diseases.
    J Gastroenterol Hepatol. 2023;38:1099-1106.
    >> Share

  66. SHEN J, Cao J, Chen M, Zhang Y, et al
    Recent advances in the role of exosomes in liver fibrosis.
    J Gastroenterol Hepatol. 2023;38:1083-1088.
    >> Share

  67. SEDAROUS M, Youssef M, Adekunle AD, Babajide O, et al
    A nationwide study of liver disease hospitalizations during the coronavirus pandemic in the United States.
    J Gastroenterol Hepatol. 2023;38:1148-1157.
    >> Share

  68. JIANG N, Xiao Y, Yuan K, Wang Z, et al
    Effect of intestinal microbiota on liver disease and its related future prospection: From the perspective of intestinal barrier damage and microbial metabolites.
    J Gastroenterol Hepatol. 2023;38:1056-1071.
    >> Share

    June 2023
  69. MINORETTI P, Emanuele E
    Reversing nonalcoholic fatty liver disease-related cirrhosis by inhibiting pyruvate kinase M2: a role for shikonin?
    J Gastroenterol Hepatol. 2023 Jun 24. doi: 10.1111/jgh.16273.
    >> Share

  70. SHARMA BC, Maharshi S, Sachdeva S, Mahajan B, et al
    Nutritional therapy for persistent cognitive impairment after resolution of overt hepatic encephalopathy in patients with cirrhosis: A double-blind randomized controlled trial.
    J Gastroenterol Hepatol. 2023 Jun 24. doi: 10.1111/jgh.16266.
    >> Share

  71. GIRI S, Singh A, Kolhe K, Kale A, et al
    Natural history of portal vein thrombosis in cirrhosis: A systematic review with meta-analysis.
    J Gastroenterol Hepatol. 2023 Jun 24. doi: 10.1111/jgh.16263.
    >> Share

  72. LIU J, Man K
    Biomarkers for monitoring alcohol sobriety after liver transplantation for alcoholic liver disease.
    J Gastroenterol Hepatol. 2023 Jun 23. doi: 10.1111/jgh.16269.
    >> Share

  73. SUZUKI Y, Maekawa S, Yamashita K, Osawa L, et al
    Effect of a combination of pemafibrate and a mild low-carbohydrate diet on obese and non-obese patients with metabolic-associated fatty liver disease.
    J Gastroenterol Hepatol. 2023;38:921-929.
    >> Share

  74. ISHIBA H, Sumida Y, Kamada Y, Fujii H, et al
    Noninvasive tests predict liver-related events and mortality in patients with nonalcoholic fatty liver disease: sub-analysis of the CLIONE-Asia study.
    J Gastroenterol Hepatol. 2023;38:896-904.
    >> Share

    May 2023
  75. TADA T, Kumada T, Hiraoka A, Hirooka M, et al
    Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2023 May 25. doi: 10.1111/jgh.16225.
    >> Share

  76. DONG Y, Liu Y, Liu X, Ma H, et al
    Multi-omics profiling of primary hepatic stellate cells from advanced liver fibrosis patients reveals distinctive molecular signatures.
    J Gastroenterol Hepatol. 2023 May 24. doi: 10.1111/jgh.16221.
    >> Share

  77. WU CW, Wong GL, Wong VW, Yam TF, et al
    Baveno VII criteria identify varices needing treatment in patients with hepatocellular carcinoma of different Barcelona Clinic Liver Cancer stages.
    J Gastroenterol Hepatol. 2023 May 22. doi: 10.1111/jgh.16218.
    >> Share

  78. ZHOU F, Mai T, Wang Z, Zeng Z, et al
    The improvement of intestinal dysbiosis and hepatic metabolic dysfunction in dextran sulfate sodium-induced colitis mice: effects of curcumin.
    J Gastroenterol Hepatol. 2023 May 20. doi: 10.1111/jgh.16205.
    >> Share

  79. KIM DS, Kim BK, Lee JS, Lee HW, et al
    Noninvasive risk assessment of hepatic decompensation in patients with hepatitis B virus-related liver cirrhosis.
    J Gastroenterol Hepatol. 2023 May 15. doi: 10.1111/jgh.16210.
    >> Share

  80. AHMED Z, Badal J, Nawras M, Battepati D, et al
    Role of rifaximin in the management of alcohol-associated hepatitis: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2023;38:703-709.
    >> Share

  81. SHIRAKAMI Y, Kato J, Maeda T, Ideta T, et al
    Skeletal muscle atrophy is exacerbated by steatotic and fibrotic liver-derived TNF-alpha in senescence-accelerated mice.
    J Gastroenterol Hepatol. 2023;38:800-808.
    >> Share

    April 2023
  82. VERMA N, Vojjala N, Mishra S, Valsan A, et al
    Machine learning can guide suitability of consultation and patient referral through telemedicine for hepatobiliary diseases.
    J Gastroenterol Hepatol. 2023 Apr 28. doi: 10.1111/jgh.16194.
    >> Share

  83. ALABBAS SY, Giri R, Oancea I, Davies J, et al
    Gut inflammation and adaptive immunity amplify acetaminophen toxicity in bowel and liver.
    J Gastroenterol Hepatol. 2023;38:609-618.
    >> Share

    March 2023
  84. MURATA K, Mizokami M
    Possible biological mechanisms of entecavir versus tenofovir disoproxil fumarate on reducing the risk of hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2023 Mar 14. doi: 10.1111/jgh.16178.
    >> Share

  85. MAO S, Liu Q, Wu H, Zhu J, et al
    Phase separation of YAP mediated by CC domain promotes hepatoblastoma proliferation via activation of transcription.
    J Gastroenterol Hepatol. 2023 Mar 12. doi: 10.1111/jgh.16173.
    >> Share

  86. MOU L, Li K, Xu C, Xu I, et al
    Construction of Endothelial Cell- and Autophagy-Related Prognostic Models for Hepatocellular Carcinoma Based on Single-Cell Data.
    J Gastroenterol Hepatol. 2023 Mar 9. doi: 10.1111/jgh.16172.
    >> Share

  87. TSUMURA S, Shimose S, Niizeki T, Kuboyama E, et al
    Telephone follow-up contributes to improving adherence and treatment duration in patients with hepatocellular carcinoma treated with lenvatinib.
    J Gastroenterol Hepatol. 2023 Mar 7. doi: 10.1111/jgh.16168.
    >> Share

  88. MNATZAGANIAN G, MacLachlan JH, Allard N, Brown C, et al
    Missed opportunities for diagnosis of hepatitis B and C in individuals diagnosed with decompensated cirrhosis or hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2023 Mar 3. doi: 10.1111/jgh.16162.
    >> Share

  89. BOUSTANY A, Onwuzo S, Zeid HKA, Almomani A, et al
    Non-alcoholic steatohepatitis is independently associated with a history of gestational diabetes mellitus.
    J Gastroenterol Hepatol. 2023 Mar 3. doi: 10.1111/jgh.16163.
    >> Share

  90. WONG GL
    Editorial: Appraising liver fibrosis with eagle eyes.
    J Gastroenterol Hepatol. 2023;38:343.
    >> Share

  91. CHEN Q, Guo J, Qiu T, Zhou J, et al
    Mechanism of ASK1 involvement in liver diseases and related potential therapeutic targets: A critical pathway molecule worth investigating.
    J Gastroenterol Hepatol. 2023;38:378-385.
    >> Share

  92. ZHAO Q, Liang L, Zhai F, Ling G, et al
    A bibliometric and visualized analysis of liver fibrosis from 2002 to 2022.
    J Gastroenterol Hepatol. 2023;38:359-369.
    >> Share

    February 2023
  93. DUNNE CL, Kaur S, Delacruz B, Bresee LC, et al
    30-day Readmission Rates Among Upper Gastrointestinal Bleeds: A Systematic Review and Meta-Analysis.
    J Gastroenterol Hepatol. 2023 Feb 20. doi: 10.1111/jgh.16153.
    >> Share

  94. ZHAO X, Shi X, Gu H, Zhou W, et al
    Association between handgrip strength, nonalcoholic fatty liver disease, advanced hepatic fibrosis and its modifiers: evidence from the NHANES database of the US.
    J Gastroenterol Hepatol. 2023 Feb 18. doi: 10.1111/jgh.16150.
    >> Share

  95. MORAN-RAMOS S, Cerqueda-Garcia D, Lopez-Contreras B, Larrieta-Carrasco E, et al
    A metagenomic study identifies a Prevotella-copri enriched microbial profile associated with non-alcoholic steatohepatitis in subjects with obesity.
    J Gastroenterol Hepatol. 2023 Feb 17. doi: 10.1111/jgh.16147.
    >> Share

  96. AAMANN L, Dam G, Jepsen P, Borre M, et al
    Reduced three-year risk of hospital admission and mortality after 12-weeks resistance training of cirrhosis patients - a follow-up of a randomized clinical trial.
    J Gastroenterol Hepatol. 2023 Feb 5. doi: 10.1111/jgh.16141.
    >> Share

  97. NOGAMI A, Iwaki M, Kobayashi T, Honda Y, et al
    Real-world assessment of SmartExam, a novel FibroScan computational method: A retrospective single-center cohort study.
    J Gastroenterol Hepatol. 2023;38:321-329.
    >> Share

  98. MOHR I, Bourhis H, Woimant F, Obadia MA, et al
    Experience on switching trientine formulations in Wilson disease: Efficacy and safety after initiation of TETA 4HCl as substitute for TETA 2HCl.
    J Gastroenterol Hepatol. 2023;38:219-224.
    >> Share

    January 2023
  99. CHO SH, Song TJ, Park JS, Yoon JH, et al
    Comparison of the long-term outcomes between proximal and distal IgG4-related sclerosing cholangitis: a multicenter cohort study.
    J Gastroenterol Hepatol. 2023 Jan 29. doi: 10.1111/jgh.16136.
    >> Share

  100. LEE HA, Lee YS, Jung YK, Kim JH, et al
    Antiviral therapy does not improve outcomes of patients with HBV-related decompensated cirrhosis and undetectable DNA.
    J Gastroenterol Hepatol. 2023 Jan 21. doi: 10.1111/jgh.16132.
    >> Share

  101. BHATEJA A, Bodh V, Chauhan A
    Role of Nutrition in the management of hepatic encephalopathy - Do we know all?
    J Gastroenterol Hepatol. 2023 Jan 21. doi: 10.1111/jgh.16131.
    >> Share

  102. ZHANG Q, Jia R, Chen M, Wang J, et al
    Antagonizing EZH2 combined with vitamin D3 exerts a synergistic role in anti-fibrosis through bidirectional effects on hepatocytes and HSCs.
    J Gastroenterol Hepatol. 2023 Jan 18. doi: 10.1111/jgh.16126.
    >> Share

  103. JANG W, Lee HW
    Hepatobiliary and Pancreatic: Hepatic mass discovered incidentally with telangiectasia.
    J Gastroenterol Hepatol. 2023 Jan 17. doi: 10.1111/jgh.16094.
    >> Share

  104. ABASSERI M, Hoque S, Kochovska S, Caldwell K, et al
    Barriers to Palliative Care in Hepatocellular Carcinoma: A Review of the Literature.
    J Gastroenterol Hepatol. 2023 Jan 12. doi: 10.1111/jgh.16107.
    >> Share

    December 2022
  105. KAZANKOV K, Nixon-Hill M, Kumar R, Amin A, et al
    A novel Smartphone scleral-image based tool for assessing jaundice in decompensated cirrhosis patients.
    J Gastroenterol Hepatol. 2022 Dec 27. doi: 10.1111/jgh.16093.
    >> Share

  106. LEE WS, Arai K, Alex G, Treepongkaruna S, et al
    Medical Management of Pediatric Inflammatory Bowel Disease (PIBD) in the Asia Pacific Region: A Position Paper by the Asian Pan-Pacific Society for Pediatric Gastroenterology, Hepatology, and Nutrition (APPSPGHAN) PIBD Working Group.
    J Gastroenterol Hepatol. 2022 Dec 27. doi: 10.1111/jgh.16097.
    >> Share

  107. AHUJA H, Sharma BC, Sachdeva S, Mahajan B, et al
    A double blind Randomized Controlled Trial to assess efficacy of Nutritional Therapy for prevention of recurrence of Hepatic Encephalopathy in patients with Cirrhosis.
    J Gastroenterol Hepatol. 2022 Dec 27. doi: 10.1111/jgh.16096.
    >> Share

  108. LONG Y, Song X, Guan Y, Lan R, et al
    Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib alone for advanced hepatocellular carcinoma: a systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2022 Dec 14. doi: 10.1111/jgh.16088.
    >> Share

  109. LEE WS, Arai K, Alex G, Treepongkaruna S, et al
    Management and Monitoring of Pediatric Inflammatory Bowel Disease (PIBD) in the Asia Pacific Region: A Position Paper by the Asian Pan-Pacific Society for Pediatric Gastroenterology, Hepatology, and Nutrition (APPSPGHAN) PIBD Working Group: Surgical M
    J Gastroenterol Hepatol. 2022 Dec 12. doi: 10.1111/jgh.16084.
    >> Share

  110. YOSHIDA S, Minaga K, Watanabe T, Kudo M, et al
    Hepatobiliary and Pancreatic: Multiple pancreatic masses with rich vascularity.
    J Gastroenterol Hepatol. 2022 Dec 5. doi: 10.1111/jgh.16060.
    >> Share

  111. SEKO Y, Kawanaka M, Fujii H, Iwaki M, et al
    Age-dependent effects of diabetes and obesity on liver-related events in non-alcoholic fatty liver disease: Subanalysis of CLIONE in Asia.
    J Gastroenterol Hepatol. 2022;37:2313-2320.
    >> Share

    November 2022
  112. KARAGIANNAKIS DS, Voulgaris T, Markakis G, Lakiotaki D, et al
    Spleen stiffness can predict liver decompensation and survival in patients with cirrhosis.
    J Gastroenterol Hepatol. 2022 Nov 8. doi: 10.1111/jgh.16057.
    >> Share

  113. OUYANG R, Li H, Tan W, Wang X, et al
    Portal vein thrombosis compromises the performance of MELD and MELD-Na scores in patients with cirrhosis.
    J Gastroenterol Hepatol. 2022 Nov 7. doi: 10.1111/jgh.16053.
    >> Share

  114. ALMOMANI A, Kumar P, Onwuzo S, Boustany A, et al
    Epidemiology and Prevalence of Lean Non-Alcoholic Fatty Liver Disease and Associated Cirrhosis, HCC and Cardiovascular Outcomes in the United States: A Population-Based Study and Review of Literature.
    J Gastroenterol Hepatol. 2022 Nov 3. doi: 10.1111/jgh.16049.
    >> Share

  115. HAKODA H, Kiritani S, Kokudo T, Yoshimura K, et al
    Probe electrospray ionization mass spectrometry-based rapid diagnosis of liver tumors.
    J Gastroenterol Hepatol. 2022;37:2182-2188.
    >> Share

    October 2022
  116. YANG Z, Wan W, Zhang P, Wang S, et al
    Crosstalk between heat shock factor 1 and signal transducer and activator of transcription 3 mediated by interleukin-8 autocrine signaling maintains the cancer stem cell phenotype in liver cancer.
    J Gastroenterol Hepatol. 2022 Oct 27. doi: 10.1111/jgh.16040.
    >> Share

  117. GORGANI F, Esfahani Z, Ghamari SH, Ghasemi E, et al
    Global, Regional, and National Burden and Quality of Care Index of Liver Cirrhosis by Cause from Global Burden of Disease 1990-2019.
    J Gastroenterol Hepatol. 2022 Oct 26. doi: 10.1111/jgh.16041.
    >> Share

  118. MEENA BL, Taneja S, Tandon P, Sahni N, et al
    Home-based Intensive Nutrition Therapy improves Frailty and Sarcopenia in Patients with Decompensated Cirrhosis: A Randomized Clinical Trial.
    J Gastroenterol Hepatol. 2022 Oct 21. doi: 10.1111/jgh.16035.
    >> Share

  119. LIU Y, Chen M
    Targeting hepatic stellate cells may serve as a promising target for hepatic steatosis.
    J Gastroenterol Hepatol. 2022 Oct 18. doi: 10.1111/jgh.16028.
    >> Share

  120. SARAIVA RO, Gamelas V, Canha MI, Carvalho D, et al
    Hepatobiliary and Pancreatic: An unusual cause of biliary obstruction.
    J Gastroenterol Hepatol. 2022 Oct 10. doi: 10.1111/jgh.16009.
    >> Share

  121. HOU G, Xu W, Ding D, Tian T, et al
    Metabolome and Transcriptome Integration Reveals Metabolic Profile of Hepatocellular Carcinoma.
    J Gastroenterol Hepatol. 2022 Oct 8. doi: 10.1111/jgh.16024.
    >> Share

  122. FERNANDEZ M, Lokan J, Leung C, Grigg A, et al
    A critical evaluation of the role of iron overload in fatty liver disease.
    J Gastroenterol Hepatol. 2022;37:1873-1883.
    >> Share

  123. LIN CL, Tai CM, Huang JF, Liu CJ, et al
    The impact of body mass index on clinicopathological features of nonalcoholic fatty liver disease in Taiwan.
    J Gastroenterol Hepatol. 2022;37:1901-1910.
    >> Share

  124. TONTIKIDOU C, Makri ES, Evripidou K, Goulis DG, et al
    Circulating adiponectin in patients with nonalcoholic fatty liver disease-related liver fibrosis: A systematic review and a meta-analysis.
    J Gastroenterol Hepatol. 2022;37:1853-1864.
    >> Share

    September 2022
  125. ZHANG C, Dai D, Zhang W, Yang W, et al
    Role of m6A RNA methylation in the development of hepatitis B virus-associated hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2022 Sep 6. doi: 10.1111/jgh.15999.
    >> Share

  126. LIM SZ, Chuah KH, Rajaram RB, Stanley K, et al
    Epidemiological trends of gastrointestinal and liver diseases in Malaysia: A single-center observational study.
    J Gastroenterol Hepatol. 2022;37:1732-1740.
    >> Share

  127. JEE JJ, Lim J, Park S, Koh H, et al
    Gut microbial community differentially characterizes patients with nonalcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2022;37:1822-1832.
    >> Share

  128. INADA K, Tamaki N, Kurosaki M, Kirino S, et al
    Validation of magnetic resonance elastography plus fibrosis-4 for significant fibrosis in nonalcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2022;37:1726-1731.
    >> Share

    August 2022
  129. PRINCE DS, Schlaphoff G, Davison SA, Huo YR, et al
    Selective internal radiation therapy for hepatocellular carcinoma: A 15-year multicenter Australian cohort study.
    J Gastroenterol Hepatol. 2022 Aug 28. doi: 10.1111/jgh.15986.
    >> Share

  130. KAWAHARA A, Kanno K, Yonezawa S, Otani Y, et al
    Depletion of hepatic stellate cells inhibits hepatic steatosis in mice.
    J Gastroenterol Hepatol. 2022 Aug 6. doi: 10.1111/jgh.15974.
    >> Share

  131. POHL K, Moodley P, Dhanda A
    The effect of increasing intestinal short-chain fatty acid concentration on gut permeability and liver injury in the context of liver disease: A systematic review.
    J Gastroenterol Hepatol. 2022;37:1498-1506.
    >> Share

  132. ZHANG H, Wang Y, Chen C, Wang B, et al
    Non-alcoholic fatty liver disease, sleep behaviors, and incident type 2 diabetes.
    J Gastroenterol Hepatol. 2022;37:1633-1640.
    >> Share

  133. HA Y, Chon YE, Kim MN, Lee JH, et al
    Gamma-glutamyl transpeptidase dynamics as a biomarker for advanced fibrosis in non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2022;37:1624-1632.
    >> Share

  134. KIM HJ, Park SJ, Park HK, Byun DW, et al
    Association of thyroid autoimmunity with nonalcoholic fatty liver disease in euthyroid middle-aged subjects: A population-based study.
    J Gastroenterol Hepatol. 2022;37:1617-1623.
    >> Share

    July 2022
  135. BINET Q, Annet L, Danse E, Goffette P, et al
    Hepatobiliary and Pancreatic: An uncommon cause of portal hypertension.
    J Gastroenterol Hepatol. 2022 Jul 28. doi: 10.1111/jgh.15961.
    >> Share

  136. LEE H, Kim BK
    Real-world clinical features, healthcare utilization, and economic burden in decompensated cirrhosis patients; a national database.
    J Gastroenterol Hepatol. 2022 Jul 21. doi: 10.1111/jgh.15962.
    >> Share

  137. FENG G, He N, Xia HH, Mi M, et al
    Machine learning algorithms based on proteomic data mining accurately predicting the recurrence of hepatitis B-related hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2022 Jul 11. doi: 10.1111/jgh.15940.
    >> Share

  138. UFUK F, Aykota MR
    Hepatobiliary and Pancreatic: Todani type I choledochal cyst and cystic malformation of the cystic duct.
    J Gastroenterol Hepatol. 2022 Jul 6. doi: 10.1111/jgh.15931.
    >> Share

  139. LONARDO A
    Precision medicine in nonalcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2022;37:1175-1178.
    >> Share

  140. GIRI S, Agarwal D, Afzalpurkar S
    GGT dynamic for advanced fibrosis in NAFLD: Novel but not convincing.
    J Gastroenterol Hepatol. 2022;37:1406.
    >> Share

    June 2022
  141. KAKIZOE M, Nagata K, Sasaki R, Ozawa E, et al
    Hepatobiliary and Pancreatic: Ruptured pseudoaneurysm after endoscopic biliary stenting using the novel double-pit-type plastic stent.
    J Gastroenterol Hepatol. 2022 Jun 27. doi: 10.1111/jgh.15913.
    >> Share

  142. LIU J, Qian Y, Yang F, Huang S, et al
    Value of prediction-model in distinguishing gallbladder adenoma from cholesterol polyp.
    J Gastroenterol Hepatol. 2022 Jun 24. doi: 10.1111/jgh.15928.
    >> Share

  143. LIU H, Yang XL, Dong ZR, Chen ZQ, et al
    Clinical Benefits of Direct-acting Antivirals Therapy in Hepatitis C Virus Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
    J Gastroenterol Hepatol. 2022 Jun 20. doi: 10.1111/jgh.15915.
    >> Share

  144. WONG YJ, Li J, Liu C, Chen Z, et al
    CHESS-ALARM score to stratify decompensation risk in compensated advanced chronic liver disease patients: An international multicenter study.
    J Gastroenterol Hepatol. 2022;37:1043-1051.
    >> Share

    May 2022
  145. DUNN W, Song X, Koestler D, Grdinovac K, et al
    Patients with type 2 diabetes and elevated fibrosis-4 are under-referred to hepatology and have unrecognized hepatic decompensation.
    J Gastroenterol Hepatol. 2022 May 25. doi: 10.1111/jgh.15900.
    >> Share

  146. CHAN SL, Wong N, Lam WKJ, Kuang M, et al
    Personalized treatment for hepatocellular carcinoma: Current status and Future perspectives.
    J Gastroenterol Hepatol. 2022 May 15. doi: 10.1111/jgh.15889.
    >> Share

  147. TENG PC, Agopian VG, Lin TY, You S, et al
    Circulating tumor cells: a step toward precision medicine in hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2022 May 11. doi: 10.1111/jgh.15886.
    >> Share

  148. CHOI AY, Kolb J, Shah S, Chahine A, et al
    Endoscopic ultrasound-guided portal pressure gradient with liver biopsy: 6 years of endo-hepatology in practice.
    J Gastroenterol Hepatol. 2022 May 5. doi: 10.1111/jgh.15875.
    >> Share

  149. WANG X, Gao X, Wu R, Chi X, et al
    Serum qAnti-HBc combined with ALT and HBsAg predicts significant hepatic inflammation in HBeAg-positive immune active patients.
    J Gastroenterol Hepatol. 2022 May 4. doi: 10.1111/jgh.15881.
    >> Share

    April 2022
  150. SHINKAI K, Sakamori R, Yamada R, Tahata Y, et al
    Prognostic impact of worsening of esophageal varices after balloon-occluded retrograde transvenous obliteration.
    J Gastroenterol Hepatol. 2022 Apr 17. doi: 10.1111/jgh.15853.
    >> Share

  151. SATO M, Kobayashi T, Soroida Y, Tanaka T, et al
    Development of novel deep multimodal representation learning-based model for the differentiation of liver tumors on B-mode ultrasound images.
    J Gastroenterol Hepatol. 2022;37:678-684.
    >> Share

  152. SASAKI Y, Abe Y, Nishise S, Yagi M, et al
    Low serum pancreatic amylase levels as a novel latent risk factor for colorectal adenoma in non-alcohol drinkers.
    J Gastroenterol Hepatol. 2022;37:660-668.
    >> Share

    March 2022
  153. LEUNG HH, Puspanathan P, Chan AW, Mustapha NRN, et al
    Reliability of the Nonalcoholic Steatohepatitis Clinical Research Network and Steatosis Activity Fibrosis histological scoring systems.
    J Gastroenterol Hepatol. 2022 Mar 31. doi: 10.1111/jgh.15843.
    >> Share

  154. HUANG X, Zhu L, Wang L, Huang W, et al
    YTHDF1 promotes intrahepatic cholangiocarcinoma progression via regulating EGFR mRNA translation.
    J Gastroenterol Hepatol. 2022 Mar 1. doi: 10.1111/jgh.15816.
    >> Share

  155. OGAWA Y, Nakahara T, Ono M, Kawaguchi T, et al
    Underestimation of impaired glucose tolerance and usefulness of a continuous glucose monitoring system in chronic liver disease.
    J Gastroenterol Hepatol. 2022;37:592-599.
    >> Share

  156. HUSSAIN I, Wong YJ, Lohan R, Lin S, et al
    Does preemptive transjugular intrahepatic portosystemic shunt improve survival after acute variceal bleeding? Systematic review, meta-analysis, and trial sequential analysis of randomized trials.
    J Gastroenterol Hepatol. 2022;37:455-463.
    >> Share

  157. YANG W, Yusufu Y, Wang C
    Gastrointestinal: A rare case of upper gastrointestinal bleeding: Splenosis mimicking gastric varices.
    J Gastroenterol Hepatol. 2022 Mar 1. doi: 10.1111/jgh.15795.
    >> Share

    February 2022
  158. LIU Y, Liu S, Huang J, Zhu Y, et al
    Validation of five hepatic steatosis algorithms in metabolic- associated fatty liver disease: a population based study.
    J Gastroenterol Hepatol. 2022 Feb 16. doi: 10.1111/jgh.15799.
    >> Share

  159. MUNDADA K, Goel A, Paliwal VK, Singh TP, et al
    Short course of low-dose pregabalin is effective for the treatment of restless leg syndrome in patients with cirrhosis: A pilot study.
    J Gastroenterol Hepatol. 2022 Feb 16. doi: 10.1111/jgh.15803.
    >> Share

  160. KEMP W, Clayton-Chubb D, Majeed A, Glenister KM, et al
    Impact of renaming NAFLD to MAFLD in an Australian regional cohort: Results from a prospective population-based study.
    J Gastroenterol Hepatol. 2022;37:395-403.
    >> Share

  161. BE KH, Zorron Cheng Tao Pu L, Apostolov R, Vaughan R, et al
    Gastrointestinal: Gastric variceal coil migration: A rare entity in endoscopy.
    J Gastroenterol Hepatol. 2022;37:281.
    >> Share

    January 2022
  162. YUAN BH, Li RH, Huo RR, Li MJ, et al
    Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta-analysis.
    J Gastroenterol Hepatol. 2022 Jan 26. doi: 10.1111/jgh.15783.
    >> Share

  163. CHAN WK, Tan SS, Chan SP, Lee YY, et al
    The Malaysian Society of Gastroenterology and Hepatology Consensus Statement on Metabolic Dysfunction-Associated Fatty Liver Disease.
    J Gastroenterol Hepatol. 2022 Jan 25. doi: 10.1111/jgh.15787.
    >> Share

  164. MOLLER S, Henriksen JH, Sjostedt S, Bendtsen F, et al
    Determination of hepatic clearance by derivations of the indocyanine green retention test in cirrhosis.
    J Gastroenterol Hepatol. 2022 Jan 11. doi: 10.1111/jgh.15778.
    >> Share

  165. YU J
    The functional role and translational potential of gut microbiota and microbial metabolites in liver diseases.
    J Gastroenterol Hepatol. 2022;37:5-6.
    >> Share

  166. LI M, Rajani C, Zheng X, Jia W, et al
    The microbial metabolome in metabolic-associated fatty liver disease.
    J Gastroenterol Hepatol. 2022;37:15-23.
    >> Share

  167. SUK KT, Koh H
    New perspective on fecal microbiota transplantation in liver diseases.
    J Gastroenterol Hepatol. 2022;37:24-33.
    >> Share

  168. PAN Y, Zhang X
    Diet and gut microbiome in fatty liver and its associated liver cancer.
    J Gastroenterol Hepatol. 2022;37:7-14.
    >> Share

    December 2021
  169. AHN HS, Kim HJ, Kang TU, Park SM, et al
    Cholecystectomy reduces the risk of cholangiocarcinoma in patients with complicated gallstones, but has negligible effect on hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2021 Dec 14. doi: 10.1111/jgh.15759.
    >> Share

  170. KERR CJ, Waterworth SP, Brodie D, Sandercock GRH, et al
    The associations between physical activity intensity, cardiorespiratory fitness, and non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2021;36:3508-3514.
    >> Share

  171. PAN J, Cen L, Zhou T, Yu M, et al
    Insulin-like growth factor binding protein 1 ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2021;36:3438-3447.
    >> Share

  172. HUANG H, Hou J, Liu K, Liu Q, et al
    RAB27A-dependent release of exosomes by liver cancer stem cells induces Nanog expression in their differentiated progenies and confers regorafenib resistance.
    J Gastroenterol Hepatol. 2021;36:3429-3437.
    >> Share

  173. SATO Y, Yoneda A, Shimizu F, Nishimura M, et al
    Resolution of fibrosis by siRNA HSP47 in vitamin A-coupled liposomes induces regeneration of chronically injured livers.
    J Gastroenterol Hepatol. 2021;36:3418-3428.
    >> Share

  174. ZHU Z, Yin J, Dawsey SM, Liu B, et al
    Association between serum ferritin, incident primary liver cancer, and chronic liver disease mortality in the Linxian Nutrition Intervention Trials: A nested case-control study.
    J Gastroenterol Hepatol. 2021;36:3410-3417.
    >> Share

    November 2021
  175. GAZELAKIS K, Mendis S, Wang S, Wong S, et al
    Hepatobiliary and Pancreatic: Liver lesions in cirrhosis: When to biopsy?
    J Gastroenterol Hepatol. 2021 Nov 22. doi: 10.1111/jgh.15735.
    >> Share

  176. KIM BH, Yu SJ, Kang W, Cho SB, et al
    Expert Consensus on the Management of Adverse Events in Patients Receiving Lenvatinib for Hepatocellular Carcinoma.
    J Gastroenterol Hepatol. 2021 Nov 1. doi: 10.1111/jgh.15727.
    >> Share

  177. POTOUPNI V, Georgiadou M, Chatzigriva E, Polychronidou G, et al
    Circulating tumor necrosis factor-alpha levels in non-alcoholic fatty liver disease: A systematic review and a meta-analysis.
    J Gastroenterol Hepatol. 2021;36:3002-3014.
    >> Share

  178. LEE S, Kim KW, Lee J, Park T, et al
    Visceral adiposity as a risk factor for lean non-alcoholic fatty liver disease in potential living liver donors.
    J Gastroenterol Hepatol. 2021;36:3212-3218.
    >> Share

  179. KUCHAY MS, Choudhary NS, Gagneja S, Mathew A, et al
    Low skeletal muscle mass is associated with liver fibrosis in individuals with type 2 diabetes and nonalcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2021;36:3204-3211.
    >> Share

    October 2021
  180. LE TV, Dinh NBT, Dang MT, Phan NCL, et al
    THE EFFECTS OF AUTOPHAGY INHIBITION BY CHLOROQUINE ON HEPATIC STELLATE CELL ACTIVATION IN CCl4 -INDUCED ACUTE LIVER INJURY MOUSE MODEL.
    J Gastroenterol Hepatol. 2021 Oct 28. doi: 10.1111/jgh.15726.
    >> Share

  181. CHANG WI, Kim BH, Kim YJ, Yoon JH, et al
    The role of radiotherapy in Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma treated with sorafenib.
    J Gastroenterol Hepatol. 2021 Oct 24. doi: 10.1111/jgh.15722.
    >> Share

  182. NAKATSU G
    Toward a postbiotic era of microbiome science: opportunities to advance immunotherapies for hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2021 Oct 19. doi: 10.1111/jgh.15715.
    >> Share

  183. CHEN T, Zhou K, Sun T, Sang C, et al
    Bile acid glycine:taurine ratios predict the progression of chronic liver disease.
    J Gastroenterol Hepatol. 2021 Oct 16. doi: 10.1111/jgh.15709.
    >> Share

  184. HUO TI, Ho SY, Liao JI
    Improved patient survival in hepatitis C virus-related hepatocellular carcinoma: Do direct-acting antivirals play a role?
    J Gastroenterol Hepatol. 2021 Oct 15. doi: 10.1111/jgh.15707.
    >> Share

  185. YIM HJ, Kim W, Ahn SH, Jung YK, et al
    Besifovir therapy improves hepatic histology and reduces covalently closed circular DNA in chronic hepatitis B patients.
    J Gastroenterol Hepatol. 2021 Oct 15. doi: 10.1111/jgh.15710.
    >> Share

  186. OGAWA E, Kawano A, Ooho A, Furusyo N, et al
    Long-term hepatic function of patients with compensated cirrhosis following successful direct-acting antiviral treatment for HCV infection.
    J Gastroenterol Hepatol. 2021 Oct 7. doi: 10.1111/jgh.15703.
    >> Share

  187. TAMAKI N, Kurosaki M, Takahashi Y, Itakura Y, et al
    Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease.
    J Gastroenterol Hepatol. 2021;36:2960-2966.
    >> Share

  188. CHEN TP, Lin WY, Chiang CH, Shen TH, et al
    Metabolically healthy obesity and risk of non-alcoholic fatty liver disease severity independent of visceral fat.
    J Gastroenterol Hepatol. 2021;36:2903-2910.
    >> Share

  189. HU HT, Wang W, Chen LD, Ruan SM, et al
    Artificial intelligence assists identifying malignant versus benign liver lesions using contrast-enhanced ultrasound.
    J Gastroenterol Hepatol. 2021;36:2875-2883.
    >> Share

  190. RODRIGUEZ-ANTONIO I, Lopez-Sanchez GN, Uribe M, Chavez-Tapia NC, et al
    Role of the inflammasome, gasdermin D, and pyroptosis in non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2021;36:2720-2727.
    >> Share

  191. WANG Y, Liu Y
    Gut-liver-axis: Barrier function of liver sinusoidal endothelial cell.
    J Gastroenterol Hepatol. 2021;36:2706-2714.
    >> Share

    September 2021
  192. LI R, Ong Q, Wong CC, Chu ES, et al
    O-GlcNAcylation inhibits hepatic stellate cell activation.
    J Gastroenterol Hepatol. 2021 Sep 21. doi: 10.1111/jgh.15690.
    >> Share

  193. LOCKART I, Hajarizadeh B, Buckley N, Davison S, et al
    All cause hepatocellular carcinoma survival in the era of direct-acting antiviral therapy.
    J Gastroenterol Hepatol. 2021 Sep 14. doi: 10.1111/jgh.15687.
    >> Share

  194. YADA S, Sasaki S, Tokuno K, Yamashita Y, et al
    Hepatobiliary and Pancreatic: Extramammary Paget disease of the esophagus.
    J Gastroenterol Hepatol. 2021 Sep 2. doi: 10.1111/jgh.15665.
    >> Share

  195. PENNISI G, Di Marco V, Buscemi C, Mazzola G, et al
    Interplay between non-alcoholic fatty liver disease and cardiovascular risk in an asymptomatic general population.
    J Gastroenterol Hepatol. 2021;36:2389-2396.
    >> Share

  196. CHEN D, Zeng R, Teng G, Cai C, et al
    Menstrual blood-derived mesenchymal stem cells attenuate inflammation and improve the mortality of acute liver failure combining with A2AR agonist in mice.
    J Gastroenterol Hepatol. 2021;36:2619-2627.
    >> Share

    August 2021
  197. ZHAO D, Xia L, Geng W, Xu D, et al
    Metformin suppresses IL-22 induced hepatocellular carcinoma by upregulating Hippo signaling pathway.
    J Gastroenterol Hepatol. 2021 Aug 25. doi: 10.1111/jgh.15674.
    >> Share

  198. EMORI T, Nuta J, Kawaji Y, Tamura T, et al
    Value of contrast-enhanced harmonic endoscopic ultrasound for diagnosing hepatic metastases of pancreatic cancer: a prospective study.
    J Gastroenterol Hepatol. 2021 Aug 16. doi: 10.1111/jgh.15661.
    >> Share

  199. OGAWA E, Nakamuta M, Furusyo N, Kajiwara E, et al
    Long-term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by DAAs.
    J Gastroenterol Hepatol. 2021 Aug 9. doi: 10.1111/jgh.15659.
    >> Share

  200. UENO M, Mano T, Kayahara T, Mizuno M, et al
    Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding: It's time to step forward.
    J Gastroenterol Hepatol. 2021 Aug 8. doi: 10.1111/jgh.15652.
    >> Share

  201. CHEN M, Hu G, Zhou X, Peng Z, et al
    Hsa_circ_0016788 regulates glycolysis and proliferation via miR-506-3p/PARP14 axis of hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2021 Aug 2. doi: 10.1111/jgh.15635.
    >> Share

  202. TAHER MK, Crispo JAG, Fortin Y, Moog R, et al
    Systemic quinolones and risk of acute liver failure III: A nested case-control study using a US electronic health records database.
    J Gastroenterol Hepatol. 2021;36:2307-2314.
    >> Share

  203. CHEN H, Johnston A, Palmer A, Mickenbecker M, et al
    Too little, too late: Palliation and end-stage liver disease.
    J Gastroenterol Hepatol. 2021;36:2303-2306.
    >> Share

    July 2021
  204. MAK J, Chan SM, Siu B, Lai J, et al
    Hepatobiliary and Pancreatic: A tree in the liver.
    J Gastroenterol Hepatol. 2021 Jul 27. doi: 10.1111/jgh.15623.
    >> Share

  205. ATTEBERRY P, Biederman B, Jesudian A, Lucero C, et al
    Mortality, Sepsis, and Organ Failure in Hospitalized Patients with Cirrhosis Vary by Type of Infection.
    J Gastroenterol Hepatol. 2021 Jul 22. doi: 10.1111/jgh.15633.
    >> Share

  206. SHI M, Sheng L, Lian M, Miao Q, et al
    Efficacy and safety of rifampicin in patients with persistent hepatocellular secretory failure.
    J Gastroenterol Hepatol. 2021 Jul 19. doi: 10.1111/jgh.15629.
    >> Share

  207. WU L, Huang XQ, Li N, Xie C, et al
    An MRI Modality for Non-invasively Distinguishing Progression of Liver Fibrosis by Visualizing Hepatic Platelet-Derived Growth Factor Receptor-Beta Expression in Mice.
    J Gastroenterol Hepatol. 2021 Jul 19. doi: 10.1111/jgh.15628.
    >> Share

  208. KRIGE J, Jonas E, Spence R, Bernon M, et al
    Letter to the editor: The complexities of predicting outcome in cirrhotic patients with acute variceal bleeding.
    J Gastroenterol Hepatol. 2021 Jul 12. doi: 10.1111/jgh.15622.
    >> Share

  209. ITO T, Hanafusa N, Soneda N, Isoai A, et al
    Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) against cirrhotic ascites in comparison with malignancy-related ascites.
    J Gastroenterol Hepatol. 2021 Jul 11. doi: 10.1111/jgh.15620.
    >> Share

  210. LIU CH, Ampuero J, Pavlides M, Wong VW, et al
    Simple non-invasive scoring systems and histological scores in predicting mortality in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2021;36:1754-1768.
    >> Share

  211. KANG HT, Jang K, Jun DW, Yoon EL, et al
    Macro-encapsulation of mesenchymal stem cells in acute and chronic liver injury animal models.
    J Gastroenterol Hepatol. 2021;36:1997-2007.
    >> Share

  212. KULKARNI AV, Anand L, Vyas AK, Premkumar M, et al
    Omega-3 fatty acid lipid emulsions are safe and effective in reducing endotoxemia and sepsis in acute-on-chronic liver failure: An open-label randomized controlled trial.
    J Gastroenterol Hepatol. 2021;36:1953-1961.
    >> Share

  213. NISHIKAWA M, Kinoshita M, Morimoto Y, Ishikiriyama T, et al
    Lipopolysaccharide preconditioning reduces liver metastasis of Colon26 cells by enhancing antitumor activity of natural killer cells and natural killer T cells in murine liver.
    J Gastroenterol Hepatol. 2021;36:1889-1898.
    >> Share

  214. YAMAMOTO K, Ikeya T, Okuyama S, Fukuda K, et al
    The association between non-alcoholic fatty liver disease (with or without metabolic syndrome) and extrahepatic cancer development.
    J Gastroenterol Hepatol. 2021;36:1971-1978.
    >> Share

    June 2021
  215. COUPER MR, Chennapragada M, Magoffin A
    Hepatobiliary and Pancreatic: A rare peribiliary lesion.
    J Gastroenterol Hepatol. 2021 Jun 29. doi: 10.1111/jgh.15556.
    >> Share

  216. ZULLO A, Soncini M, Bucci C, Marmo R, et al
    Clinical outcomes in cirrhotics with variceal or nonvariceal gastrointestinal bleeding: a prospective, multicenter cohort study.
    J Gastroenterol Hepatol. 2021 Jun 29. doi: 10.1111/jgh.15601.
    >> Share

  217. HO SY, Liu PH, Hsu CY, Ko CC, et al
    Tumor burden score as a new prognostic marker for patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
    J Gastroenterol Hepatol. 2021 Jun 22. doi: 10.1111/jgh.15593.
    >> Share

  218. PHRUEKSOTSAI S, Pinyopornpanish K, Euathrongchit J, Leerapun A, et al
    Dapagliflozin reduces hepatic and visceral fat in type-2 diabetes patients with non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2021 Jun 15. doi: 10.1111/jgh.15580.
    >> Share

  219. FAJARDO J, Nunez E, Szafranska J, Poca M, et al
    We report a patient who presented intrahepatic cholangitis and cholecystitis after SARS-CoV-2 infection.
    J Gastroenterol Hepatol. 2021 Jun 9. doi: 10.1111/jgh.15537.
    >> Share

  220. CHUN HS, Lee JS, Lee HW, Kim BK, et al
    Association between the severity of liver fibrosis and cardiovascular outcomes in patients with type 2 diabetes.
    J Gastroenterol Hepatol. 2021;36:1703-1713.
    >> Share

  221. HASSANI ZADEH S, Mansoori A, Hosseinzadeh M
    Relationship between dietary patterns and non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2021;36:1470-1478.
    >> Share

  222. AHADI M, Molooghi K, Masoudifar N, Namdar AB, et al
    A review of non-alcoholic fatty liver disease in non-obese and lean individuals.
    J Gastroenterol Hepatol. 2021;36:1497-1507.
    >> Share

  223. RHODES FA, Trembling P, Panovska-Griffiths J, Tanwar S, et al
    Systematic review: Investigating the prognostic performance of four non-invasive tests in alcohol-related liver disease.
    J Gastroenterol Hepatol. 2021;36:1435-1449.
    >> Share

  224. LV T, Chen S, Li M, Zhang D, et al
    Regional variation and temporal trend of primary biliary cholangitis epidemiology: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2021;36:1423-1434.
    >> Share

  225. LIU D, Shen Y, Zhang R, Xun J, et al
    Prevalence and risk factors of metabolic associated fatty liver disease among people living with HIV in China.
    J Gastroenterol Hepatol. 2021;36:1670-1678.
    >> Share

  226. HUANG Y, Huang F, Yang L, Hu W, et al
    Development and validation of a radiomics signature as a non-invasive complementary predictor of gastroesophageal varices and high-risk varices in compensated advanced chronic liver disease: A multicenter study.
    J Gastroenterol Hepatol. 2021;36:1562-1570.
    >> Share

  227. YIP TC, Wong VW, Wong GL
    Liver-heart connection in diabetes mellitus.
    J Gastroenterol Hepatol. 2021;36:1385-1386.
    >> Share

    May 2021
  228. ZHOU J, Wang C, Chen Z
    Hepatobiliary and Pancreatic: Castleman disease of the pancreas diagnosed by endoscopic ultrasound.
    J Gastroenterol Hepatol. 2021 May 31. doi: 10.1111/jgh.15520.
    >> Share

  229. KANEKO S, Kurosaki M, Inada K, Kirino S, et al
    Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients.
    J Gastroenterol Hepatol. 2021 May 31. doi: 10.1111/jgh.15563.
    >> Share

  230. AGARWAL S, Sharma S, Kumar M, Venishetty S, et al
    Development of a machine learning model to predict bleed in esophageal varices in compensated advanced chronic liver disease: A proof of concept.
    J Gastroenterol Hepatol. 2021 May 28. doi: 10.1111/jgh.15560.
    >> Share

  231. MA HL, Chen SD, Zheng KI, Yu Y, et al
    The TA allele of rs2070673 in the CYP2E1 gene is associated with lobular inflammation and nonalcoholic steatohepatitis in patients with biopsy-proven nonalcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2021 May 24. doi: 10.1111/jgh.15554.
    >> Share

  232. TAK KY, Jang B, Lee SK, Nam HC, et al
    The prognostic role of M2BPGi compared with the HAP score in hepatocellular carcinoma patients receiving transarterial treatment.
    J Gastroenterol Hepatol. 2021 May 24. doi: 10.1111/jgh.15553.
    >> Share

  233. ZHAO JA, Nie W, Dong L, Liu W, et al
    A curcumin analogue GL63 inhibits the malignant behaviors of hepatocellular carcinoma by inactivating the JAK2/STAT3 signaling pathway via the circZNF83/miR-324-5p/CDK16 axis.
    J Gastroenterol Hepatol. 2021 May 12. doi: 10.1111/jgh.15545.
    >> Share

  234. CHANG H, Li J, Luo Y, Wu B, et al
    TFB2M activates aerobic glycolysis in hepatocellular carcinoma cells through the NAD(+) /SIRT3/HIF-1alpha signaling.
    J Gastroenterol Hepatol. 2021 May 12. doi: 10.1111/jgh.15548.
    >> Share

  235. YANG C, Liu J, Shi Q, Huang S, et al
    Effect of splenectomy on the outcomes in patients with cirrhosis receiving transjugular intrahepatic portosystemic shunt.
    J Gastroenterol Hepatol. 2021 May 11. doi: 10.1111/jgh.15543.
    >> Share

  236. XIE JM, Liu JH, Sun YH, Li W, et al
    Hepatobiliary and Pancreatic: Endoscopic resection of biliary ductal tumour.
    J Gastroenterol Hepatol. 2021 May 9. doi: 10.1111/jgh.15518.
    >> Share

  237. HSU WF, Tsai PC, Chen CY, Tseng KC, et al
    Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (T-COACH).
    J Gastroenterol Hepatol. 2021 May 7. doi: 10.1111/jgh.15538.
    >> Share

  238. CHEN Z, Jiang H, Wang Y, Liang R, et al
    Three-day Postoperative Antibiotics Reduces Post-hepatectomy Infection Rate in HBV-related Hepatocellular Carcinoma.
    J Gastroenterol Hepatol. 2021 May 4. doi: 10.1111/jgh.15528.
    >> Share

  239. ANAND A, Elhence A, Vaishnav M, Singh AA, et al
    FibroScan-aspartate aminotransferase score in an Asian cohort of non-alcoholic fatty liver disease and its utility in predicting histological resolution with bariatric surgery.
    J Gastroenterol Hepatol. 2021;36:1309-1316.
    >> Share

  240. LI X, Qin P, Cao L, Lou Y, et al
    Dose-response association of the ZJU index and fatty liver disease risk: A large cohort in China.
    J Gastroenterol Hepatol. 2021;36:1326-1333.
    >> Share

  241. TANDON R, Froghi S
    Artificial liver support systems.
    J Gastroenterol Hepatol. 2021;36:1164-1179.
    >> Share

    April 2021
  242. PUDIPEDDI A, Han J, Leong R
    Hepatobiliary and Pancreatic: Right upper quadrant pain and positive Murphy's sign.
    J Gastroenterol Hepatol. 2021 Apr 29. doi: 10.1111/jgh.15510.
    >> Share

  243. KAPURIA D, Bollipo S, Rabiee A, Ben-Yakov G, et al
    Roadmap to resuming care for liver diseases after coronavirus disease-2019.
    J Gastroenterol Hepatol. 2021;36:885-892.
    >> Share

  244. CHRYSAVGIS L, Papatheodoridi AM, Chatzigeorgiou A, Cholongitas E, et al
    The impact of sodium glucose co-transporter 2 inhibitors on non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2021;36:893-909.
    >> Share

  245. SHIGEFUKU R, Iwasa M, Eguchi A, Tamai Y, et al
    Serum copeptin level is a biomarker associated with ascites retention and the formation of a portosystemic shunt in chronic liver disease.
    J Gastroenterol Hepatol. 2021;36:1006-1014.
    >> Share

    March 2021
  246. SUNG YS, Park B, Park HJ, Lee SS, et al
    Radiomics and deep learning in liver diseases.
    J Gastroenterol Hepatol. 2021;36:561-568.
    >> Share

  247. WONG GL, Yuen PC, Ma AJ, Chan AW, et al
    Artificial intelligence in prediction of non-alcoholic fatty liver disease and fibrosis.
    J Gastroenterol Hepatol. 2021;36:543-550.
    >> Share

  248. LEE HW, Sung JJY, Ahn SH
    Artificial intelligence in liver disease.
    J Gastroenterol Hepatol. 2021;36:539-542.
    >> Share

    February 2021
  249. VADARLIS A, Antza C, Bakaloudi DR, Doundoulakis I, et al
    Systematic review with meta-analysis: The effect of vitamin E supplementation in adult patients with non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2021;36:311-319.
    >> Share

    January 2021
  250. YOSHINO K, Taura K, Iwaisako K, Masano Y, et al
    A novel mouse model for cholestasis-induced liver fibrosis resolution by cholecystojejunostomy.
    J Gastroenterol Hepatol. 2021 Jan 15. doi: 10.1111/jgh.15406.
    >> Share

  251. LUM JHM, Cheah MCC, Leow WQ, Wan WK, et al
    Clinical profile of non-alcoholic fatty liver disease in nonobese patients.
    J Gastroenterol Hepatol. 2021;36:257-261.
    >> Share

  252. GRONBAEK H, Moller HJ, Saliba F, Zeuzem S, et al
    Improved prediction of mortality by combinations of inflammatory markers and standard clinical scores in patients with acute-on-chronic liver failure and acute decompensation.
    J Gastroenterol Hepatol. 2021;36:240-248.
    >> Share

    October 2020
  253. YANG J, Sontag D, Gong Y, Minuk GY, et al
    Enhanced Gemcitabine Cytotoxicity with Knockdown of Multidrug Resistance Protein Genes in Human Cholangiocarcinoma Cell Lines.
    J Gastroenterol Hepatol. 2020 Oct 1. doi: 10.1111/jgh.15289.
    >> Share

    September 2020
  254. PYO JH, Kim TJ, Lee H, Choi SC, et al
    Proton Pump Inhibitors Use and the Risk of Fatty Liver Disease; A Nationwide Cohort Study.
    J Gastroenterol Hepatol. 2020 Sep 4. doi: 10.1111/jgh.15236.
    >> Share

    August 2020
  255. EFE C, Torgutalp M, Henriksson I, Alalkim F, et al
    Extrahepatic autoimmune diseases in primary biliary cholangitis: prevalence, significance for clinical presentation and disease outcome.
    J Gastroenterol Hepatol. 2020 Aug 13. doi: 10.1111/jgh.15214.
    >> Share

    July 2020
  256. KIM KS, Kwon HM, Jung KW, Sang BH, et al
    Markedly prolonged QTc interval in end-stage liver disease and risk of 30-day cardiovascular event after liver transplant.
    J Gastroenterol Hepatol. 2020 Jul 13. doi: 10.1111/jgh.15179.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016